FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)

Cervical Cancer Clinical Trial

— HPVDNA02  

Official title:

FDG-PET and Circulating HPV in Patients With Cervical Cancer Treated With Definitive Chemoradiation (II)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03853915
• Other study ID #: 18-6277
• Status: Recruiting
• Phase: N/A
• Start date: April 23, 2019
• Est. completion date: December 30, 2026

Study information

• Verified date: June 2024
• Source: University Health Network, Toronto
• Contact: Kathy Han, MD
• Phone: 416 946 4501
• Email: kathy.han[@]rmp.uhn.ca
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Nearly all cervical cancers are caused by the human papilloma virus (HPV), which can be detected in cancer tissue by laboratory tests. There is evidence that the virus can also be detected from a blood sample to monitor the effects of treatment. Previous studies have shown that a special test called 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET-CT) at 3 months after treatment may predict survival in cervical cancer.

The purpose of this study is to see how well the FDG-PET Scan and blood tests for HPV can detect leftover cervical cancer cells after treatment. This study is not a particular form of treatment and patients will receive standard of care treatment.

Description:

Cervical cancer is the 4th most common malignancy in women worldwide. A significant proportion of women with locally advanced cervical cancer are primarily managed with chemotherapy and radiotherapy which has improved the 5-year survival and disease-free survival; however both local and distant recurrences still remain to be challenges after treatment.

A prospective study has shown that metabolic response on post-therapy FDG-PET scan at 3 months to be predictive of progression-free and overall survival in patients with locally advanced cervical cancer. It may also predict patterns of failures for these patients.

HPV is recognized as a necessary cause of the vast majority of cervical cancer and HPV DNA has been detected in circulation from patients with cervical cancer and oropharyngeal cancer at diagnosis and at the time of relapse. Despite the promising potential of HPV DNA to monitor response and detect recurrence at an early stage, no study has evaluated serial HPV DNA and its association with PET response and survival.

We have recently reported preliminary data from a feasibility study (HPVDNA01) on 20 patients. Detectable HPV DNA at the end of cervical radiation therapy predated the clinical diagnosis of metastases and was associated with inferior progression-free survival. Also, 3 month plasma HPV DNA level was more accurate than 3-month FDG PET imaging in detecting leftover disease. This follow-up study aims to validate the clinical utility of plasma HPV DNA detection.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 64
• Est. completion date: December 30, 2026
• Est. primary completion date: December 30, 2026
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma of the cervix, FIGO stage IB-IVA

• 3.1.2 Planned for radical radiotherapy and concurrent cisplatin chemotherapy.

• 3.1.3 Age = 18 years.

Exclusion Criteria:

• Evidence of distant metastases (suspicious paraaortic nodes below the renal vessels allowed if they will be encompassed within the radiation field)

• Patients who have received any anticancer treatment for their cervical cancer.

• Other cervical cancer tumor histologies (e.g. small cell, serous)

• Contraindications to 18FDG PET-CT

• Contraindication to radiotherapy (e.g. severe Crohn's disease)

• Contraindication to chemotherapy (e.g. non-reversible renal failure)

• History of another invasive malignancy, except for non-melanoma skin cancer or tumors curatively treated with no evidence of disease for = 5 years.

• Known pregnancy or lactating

Related Conditions & MeSH terms

• Cervical Cancer
• Uterine Cervical Neoplasms

Intervention

Diagnostic Test:
• [18-F]- FDG - PET
[F-18]-FDG Injection is an intravenous diagnostic radiopharmaceutical used for Positron Emission Tomography. While this is not the subject of investigation in this study, [F-18]-FDG will be used in the PET imaging assessment of study participants during their 3 month follow-up post-treatment.

Locations

Country	Name	City	State
Canada	University Health Network, The Princess Margaret	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
University Health Network, Toronto	Sunnybrook Health Sciences Centre

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival rate	The progression-free survival rate of patients with and without detectable plasma HPV DNA post treatment	up to 5 years
Secondary	Plasma HPV DNA levels	The accuracy of 3-month FDG-PET or 3-month HPV DNA for predicting relapse will be estimated.	Up to 3 months